AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015
OREANDA-NEWS. September 01, 2015. Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus on the early management of Acute Coronary Syndromes (ACS) and long-term secondary prevention of atherothrombotic events in patients who have previously suffered a heart attack.
Presentation of the data, including sub-analyses of the BRILINTA® PEGASUS-TIMI 54 study, coincides with updates to the ESC guidelines on treatment of Non-ST Segment Elevation Myocardial Infarction patients, which will be presented at the congress on Sunday, 30 August. The updated guidelines will provide insight into long term dual antiplatelet therapy for patients with a history of heart attack.
The PEGASUS-TIMI 54 study sub-analyses will provide further understanding of the types of patients most likely to benefit from long-term treatment with BRILINTA. The data will also provide insight into the relationship between the time from a patient’s last treatment with P2Y12 antiplatelet therapy and their risk of a subsequent heart attack, stroke or cardiovascular death as well as the effect of BRILINTA in this setting.
Elisabeth Bj?rk, Vice President, Head of Cardiovascular and Metabolic Diseases, Global Medicines Development, AstraZeneca, said: “It is encouraging to see guideline updates recognise the continuing risk for patients more than one year after their heart attack and consider how this risk can be managed. We are looking forward to the presentation of the PEGASUS-TIMI 54 sub-analyses during the ESC Congress 2015 and to continuing the debate about the long-term use of dual antiplatelet therapy for these patients.”
In March 2015, based on the results of the PEGASUS-TIMI 54 study1, the US Food and Drug Administration (FDA) granted Priority Review for BRILINTA for the prevention of atherothrombotic events in patients who have previously experienced a heart attack.
Additional sub-analyses of the PEGASUS-TIMI 54 study also being presented at the ESC Congress 2015 include research into the relationship between renal function and risk of ischaemic and bleeding events, evaluated in a subset of high-risk patients with reduced renal function, and a gender comparison sub-analysis, assessing the relative safety and efficacy of ticagrelor in women versus men.
Other data highlights at the ESC Congress 2015 include:
• Data from the APOLLO real-world evidence study, exploring the impact of associated risk factors (such as age ?65 years, diabetes, history of >1 prior myocardial infarction or renal disease) on the likelihood of recurrent cardiovascular events [abstract P2467], as well as long-term national healthcare costs post-heart attack [abstract 3662], will be featured as poster presentations on Sunday 30 August and Monday 31 August.
• Data from the ATLANTIC-H24 analysis, exploring the effect of pre-hospital versus
in-hospital administration of ticagrelor during the first 24 hours post-procedure, specifically among patients who underwent percutaneous coronary intervention (PCI), will feature on Monday 31 August, as part of the Clinical Trial Update II - Antiplatelet therapy session [abstract 3914].
• Two additional sub-analyses from ATLANTIC, exploring the study results according to gender [abstract P551] and within the French sub-population [abstract P556] will also be featured as poster presentations.
• Data from the SUPPORT study demonstrating the impact of a new interactive smartphone application on improving patient adherence and quality of life [abstract 6649] will be explored during a rapid fire abstract session on Wednesday 2 September.
• A VOYAGER meta-analysis examining the role of statin therapy, such as CRESTOR® (rosuvastatin) [poster P6465], in risk of atherosclerotic cardiovascular disease over a 10 year period will be presented in a poster session on Tuesday 1 September.
ASTRAZENECA ABSTRACTS TO BE FEATURED AT THE ESC CONGRESS 2015
Abstract #, Title and Author | Time (BST) / Session |
|---|---|
|
BRILINTA abstracts |
|
|
Abstract P551 Worse short-term outcome for women with STEMI. Insights from the ATLANTIC study Swahn E, et al |
Saturday 29 August 11:00 – 16:00 Poster session 1: Infarction acute phase STEMI II |
|
Abstract P556 Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: the French subgroup analysis of the ATLANTIC study Cayla G, et al |
Saturday 29 August 11:00 – 16:00 Poster session 1: Infarction acute phase STEMI III |
|
Abstract P1115 Dual anti-thrombotic effects of ticagrelor on Arterial Thrombosis: an anti-platelet agent with anti-coagulant properties Reiner MF, et al |
Sunday 30 August Moderated poster presentation 10:34 – 10:42 Session: Clinical impact and modulation of endothelial (dys)function |
|
Abstract P2463 High event rate in patients with acute coronary syndromes and atrial fibrillation: Results from the prospective EPICOR Registry Zeymer U, et al |
Sunday 30 August 14:00 – 18:00 Poster session 3: STEMI I |
|
Abstract 3032 Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: Insights from the PEGASUS-TIMI 54 trial Magnani G, et al |
Monday 31 August Oral presentation 09:24 – 09:41 Session: Antithrombotic drugs - An ongoing research |
|
Abstract P3317 The efficacy and safety of ticagrelor in women versus men with a prior myocardial infarction: Insights from the PEGASUS-TIMI 54 trial O’Donoghue M, et al |
Monday 31 August 10:00 – 11:00 Best posters session 4 |
|
Abstract P3318 Ticagrelor 60 mg twice-daily provides effective platelet inhibition in patients with prior myocardial infarction – the PEGASUS-TIMI 54 platelet function substudy Storey R, et al |
Monday 31 August 10:00 – 11:00 Best posters session 4 |
|
Abstract 3914 Effect of pre-hospital ticagrelor in STEMI patients in the first 24 hours after primary PCI: The ATLANTIC-H24 analysis Montalescot G, et al |
Monday 31 August Rapid fire abstract 14:15 – 14:30 Session: Clinical Trial Update II - Antiplatelet therapy |
|
Abstract 3918 Ischemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal Bonaca MP, et al |
Monday 31 August Oral presentation 15:15 – 15:30 Session: Clinical Trial Update II - Antiplatelet therapy |
|
ACS abstracts |
|
|
Abstract P172 Biomarker-based prediction model for recurrent ischemic events in revascularized patients with acute coronary syndromes Lindholm D, et al |
Saturday 29 August Moderated poster presentation 12:38 – 12:47 Session: Post infarction period |
|
Abstract P2467 Cardiovascular risk in post-myocardial infarction patients: Nationwide real-world data on distribution and impact of combination of risk factors in a real-life setting Jernberg T, et al |
Sunday 30 August 14:00 – 18:00 Poster session 3: STEMI I |
|
Abstract 3662 Long-term healthcare costs after myocardial infarction in a clinical practice setting in Sweden; results from a contemporary nationwide registry study Janzon M, et al |
Monday 31 August 08:30 – 12:30 Poster session 4: Improvement of medical care in cardiovascular patients: social and economic issues |
|
Abstract 3030 Effect of Time to interventional treatment on NSTE-ACS Outcomes in PLATO Pollack C, et al |
Monday 31 August Oral presentation 08:50 – 09:07 Session: Antithrombotic drugs - An ongoing research |
|
Abstract 3031 Treatment and long-term results of acute coronary syndrome (ACS) in patients on chronic oral anticoagulants (OAC): data from the EPICOR (NCT01171404) study Stepinska J, et al |
Monday 31 August Oral presentation 09:07 – 09:24 Session: Antithrombotic drugs - An ongoing research |
|
Abstract P3319 Differences in dual antiplatelet treatment for acute coronary syndrome patients undergoing PCI or not: a Danish nationwide population-based cohort study Gislason G, et al |
Monday 31 August 10:00 – 11:00 Best posters session 4 |
|
Abstract P5340 Prognostic value of elevated high-sensitivity cardiac troponin T levels in patients with stable coronary artery disease Biener M, et al |
Tuesday 1 September 08:30 – 12:30 Poster session 6: Coronary artery disease and comorbidities I |
|
Abstract 4972 Treatment pattern of dual antiplatelet therapy in 104,012 patients with acute coronary syndrome; a Swedish nationwide population based cohort study Angeras O, et al |
Tuesday 1 September Rapid fire abstract 08:39 – 08:48 Session: Flash news on antithrombotics |
|
Abstract 4975 Balancing the risk of ischaemic and bleeding events in ACS Ducrocq G, et al |
Tuesday 1 September Rapid fire abstract 08:57 – 09:06 Session: Flash news on antithrombotics |
|
Abstract 6649 Effects of interactive patient support with a smartphone app on drug adherence and lifestyle changes in myocardial infarction patients Varenhorst C, et al |
Wednesday 2 September Rapid fire abstract 08:57 – 09:06 Session: Cardiovascular prevention: what works for whom? |
|
Abstract 6654 Health outcomes and platelet-aggregation inhibition after acute myocardial infarction in clinical practice. Findings from the PIPER study Esposti LD, et al |
Wednesday 2 September Rapid fire abstract 09:42 – 09:51 Session: Cardiovascular prevention: what works for whom? |
|
CRESTOR abstracts |
|
|
Abstract P6465 Estimating the reduction in 10-year atherosclerotic cardiovascular disease risk with statin therapy: a VOYAGER meta-analysis Karlson B, et al |
Tuesday 1 September 14:00 – 18:00 Poster session 7: Surveillance of risk factors and interventions |
|
Abstract P6551 YKL-40 in chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA) Kanwal AF, et al |
Tuesday 1 September 14:00 – 18:00 Poster session 7: Prognosis II |
NOTES TO EDITORS
1 Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800.
About BRILINTA®
BRILINTA is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). BRILINTA works by inhibiting platelet activation.
BRILINTA (90mg) is indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with ACS (unstable angina [UA], non–ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). BRILINTA has been shown to reduce the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with percutaneous coronary intervention, it also reduces the rate of stent thrombosis.
BRILINTA is a registered trademark of the AstraZeneca group.
About the PEGASUS TIMI-54 study
PEGASUS-TIMI 54 (PrEvention with TicaGrelor of SecondAry Thrombotic Events in High-RiSk Patients with Prior AcUte Coronary Syndrome – Thrombolysis In Myocardial Infarction Study Group) is one of AstraZeneca’s largest ever outcomes trials with more than 21,000 patients from over 1,100 sites in 31 countries in Europe, the Americas, Africa and Australia/Asia. It was conducted in collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group from Brigham and Women’s Hospital (Boston, MA, USA).
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:www.astrazeneca.com
Комментарии